Vertex Pharmaceuticals (VRTX) Intangibles (2009 - 2026)

Vertex Pharmaceuticals has reported Intangibles for 18 years, with the latest figure at $412.8 million in Q2 2026.

• On a quarterly basis, Intangibles fell 5.21% year-over-year to $412.8 million in Q2 2026; TTM through Jun 2026 was $412.8 million, a 5.21% decrease from a year earlier, with the FY2025 full-year figure at $424.2 million, down 48.64% from the prior year.
• Intangibles was $412.8 million for Q2 2026 at Vertex Pharmaceuticals, down from $418.5 million in the prior quarter.
• The five-year high for Intangibles was $839.9 million in Q4 2023, with the low at $387.0 million in Q2 2022.
• Average Intangibles over 5 years is $585.4 million, with a median of $603.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Intangibles surged 55.97% in 2023, then sank 48.64% in 2025.
• Over 5 years, Intangibles stood at $603.6 million in 2022, then surged by 39.15% to $839.9 million in 2023, then decreased by 1.67% to $825.9 million in 2024, then tumbled by 48.64% to $424.2 million in 2025, then dropped by 2.69% to $412.8 million in 2026.
• The last three Intangibles figures came in at $412.8 million (Q2 2026), $418.5 million (Q1 2026), and $424.2 million (Q4 2025), per Business Quant data.